

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

Brilliant Violet 421(TM) anti-mouse/human CD44

RRID:AB_10895752

Type: Antibody

Proper Citation

BioLegend Cat# 103039, RRID:AB_10895752

Antibody Information

URL: http://antibodyregistry.org/AB_10895752

Proper Citation: BioLegend Cat# 103039, RRID:AB_10895752

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-P

Antibody Name: Brilliant Violet 421(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_10895752

Vendor: BioLegend

Catalog Number: 103039

Alternative Catalog Numbers: 103040

Record Creation Time: 20250820T054516+0000

Record Last Update: 20250820T222255+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Geng S, et al. (2026) Krüppel-like factor 2 programs early exhausted T cell states and restrains antiviral immunity. *Immunity*, 59(5), 1306.

Kureshi CTS, et al. (2026) Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. *Cancer cell*, 44(7), 1381.

Zhang Y, et al. (2026) Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice. *Cell host & microbe*, 34(2), 212.

Zhang G, et al. (2025) Myeloid-lineage-specific membrane protein LRRC25 suppresses immunity in solid tumor and is a potential cancer immunotherapy checkpoint target. *Cell reports*, 44(5), 115631.

Ingelshed K, et al. (2025) Protocol for in vivo immune cell analysis in subcutaneous murine tumor models using advanced flow cytometry. *STAR protocols*, 6(1), 103505.

Sharma P, et al. (2025) Smoking-induced gut microbial dysbiosis mediates cancer progression through modulation of anti-tumor immune response. *iScience*, 28(3), 112002.

Forcella P, et al. (2024) SAFB regulates hippocampal stem cell fate by targeting Drosha to destabilize Nfib mRNA. *eLife*, 13.

Benguigui M, et al. (2024) Interferon-stimulated neutrophils as a predictor of immunotherapy response. *Cancer cell*, 42(2), 253.

Sekiya T, et al. (2024) Tonic TCR and IL-1? signaling mediate phenotypic alterations of naive CD4+ T cells. *Cell reports*, 43(3), 113954.

Nguele Meke F, et al. (2024) Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models. *Cancer research communications*, 4(1), 5.

Ingelshed K, et al. (2024) MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors. *iScience*, 27(6), 109862.

Shao TY, et al. (2023) Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation. *Cell reports*, 42(11), 113323.

Adamska JZ, et al. (2023) Ablation of Adar1 in myeloid cells imprints a global antiviral state in the lung and heightens early immunity against SARS-CoV-2. *Cell reports*, 42(1), 112038.

Cohen GS, et al. (2023) Transplantation elicits a clonally diverse CD8+ T cell response that is comprised of potent CD43+ effectors. *Cell reports*, 42(8), 112993.

Yadavilli S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. *Cancer research communications*, 3(8), 1564.

Freshour SL, et al. (2023) Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer. *iScience*, 26(10), 107937.

Ma S, et al. (2022) Heterochronic parabiosis induces stem cell revitalization and systemic rejuvenation across aged tissues. *Cell stem cell*, 29(6), 990.

Kurz E, et al. (2022) Exercise-induced engagement of the IL-15/IL-15R α axis promotes anti-tumor immunity in pancreatic cancer. *Cancer cell*, 40(7), 720.

Marangoni F, et al. (2021) Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. *Cell*, 184(15), 3998.

Zebley CC, et al. (2021) Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation. *Cell reports*, 37(2), 109796.